)
)
)
MitoChem Therapeutics
Our lead asset reverses a neurotoxic gain of function of a protein genetically linked to neurodegeneration. MitoChem's small molecule lead is first-in-class to target Fused in Sarcoma (FUS) with a novel mechanism of action with disease modifying potential in ALS, FTD and Retinal Degeneration. With multiple related compounds in its pipeline, MitoChem is uniquely positioned to address large, underserved markets with blockbuster potential.
Address
CharlestonSouth Carolina
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)